EP PerMed published PARADISE as an example of a successful story

EP PerMed (European Partnership for Personalised Medicine) has published the PARADISE project (PersonAlisation of RelApse risk in autoimmune DISEase) as an example of a successful story.

By showcasing success stories, outstanding achievements and results in the field of personalised medicine are emphasised, aiming to inspire the scientific community, engage stakeholders, and inform the public. This also underscores the commitment of international consortia. The Catholic University of Croatia, led by Assoc. Prof. Dr. Anto Čartolovni, participating as a project partner alongside institutions from Ireland, Sweden, Germany, Belgium, France, and Spain.

The multidisciplinary consortium of experts from seven countries integrates top expertise in medicine, biomarkers, artificial intelligence, and ethics. The Catholic University of Croatia is responsible for ensuring responsible innovation through ethical guidance and patient involvement. Patient involvement is at the core of the PARADISE project, ensuring the tool aligns with patients' needs and expectations. Find more about patient involvement at the link.

The PARADISE project, funded under ERA PerMed’s JTC2022 call aims to develop a personalised tool that accurately assesses individual immune system activation. By tailoring drug dosages, PARADISE seeks to redefine autoimmune disease monitoring, ultimately improving patient care and quality of life.

Read the full story published on the EP PerMed portal at the link.